Summary of the pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Postby gwa » Tue Sep 25, 2007 11:05 am

dignan,

I would find it interesting to see how many of the new trials are being sponsored by and combined with other CRABS.

The latest one just posted (green tea) is being combined with Copaxone (and paid for, I assume, by Teva) as is the estriol trial being conducted at UCLA.

Some of these trials are starting to smell to me because if the products work, it looks like Copaxone and other CRAB companies will also be part of the treatment option, whether necessary or not.

gwa
User avatar
gwa
Family Elder
 
Posts: 846
Joined: Thu Dec 01, 2005 4:00 pm

Postby dignan » Wed Sep 26, 2007 9:29 am

Somebody tipped me off that one of the pre-clinical substances has moved all the way to phase 2. It's Sanofi-Aventis' HP184, now called nerispirdine. It's a K+ / Na+ channel blocker.
User avatar
dignan
Family Elder
 
Posts: 1608
Joined: Wed Aug 11, 2004 3:00 pm

Postby dignan » Wed Sep 26, 2007 9:35 am

Good question about how many trials are being done with CRABs. I don't have an answer right now.
User avatar
dignan
Family Elder
 
Posts: 1608
Joined: Wed Aug 11, 2004 3:00 pm

ATX-MS-1467

Postby bromley » Wed Sep 26, 2007 1:38 pm

Dignan,

I couldn't see this on your list (sorry if I missed it). Should be in Phase 1 treatments.


http://www.apitope.com/apitopepress_03.html

A bit on the company and the timelines (company spun out from Bristol University, UK)

http://www.apitope.com/aboutapitope.html
User avatar
bromley
Family Elder
 
Posts: 1887
Joined: Fri Sep 10, 2004 3:00 pm

Postby dignan » Wed Sep 26, 2007 6:11 pm

Thanks for the info Ian. I will add it.
User avatar
dignan
Family Elder
 
Posts: 1608
Joined: Wed Aug 11, 2004 3:00 pm

Postby dignan » Mon Oct 29, 2007 8:27 am

As I posted in a separate thread today, Bayer announced that the trial of the 500 mcg dose of betaseron failed to achieve it's primary endpoint. I removed it from the list.
User avatar
dignan
Family Elder
 
Posts: 1608
Joined: Wed Aug 11, 2004 3:00 pm

Postby Lyon » Thu Nov 01, 2007 1:12 pm

.
Last edited by Lyon on Sat Dec 03, 2011 6:56 pm, edited 1 time in total.
Lyon
Family Elder
 
Posts: 6063
Joined: Wed May 03, 2006 3:00 pm

Postby dignan » Thu Nov 01, 2007 2:05 pm

Bob, thanks for getting that info straight from the horse's mouth. I'll change the list.
User avatar
dignan
Family Elder
 
Posts: 1608
Joined: Wed Aug 11, 2004 3:00 pm

Postby Lyon » Thu Nov 01, 2007 2:08 pm

.
Last edited by Lyon on Sat Dec 03, 2011 6:56 pm, edited 1 time in total.
Lyon
Family Elder
 
Posts: 6063
Joined: Wed May 03, 2006 3:00 pm

Postby dignan » Mon Nov 12, 2007 9:59 am

Added Amiloride to phase 1 based on an article posted by Frank and Bromley.
User avatar
dignan
Family Elder
 
Posts: 1608
Joined: Wed Aug 11, 2004 3:00 pm

Postby dignan » Thu Dec 13, 2007 9:41 am

Ofatumumab is already on the list in phase 2. Here are details of the upcoming phase 2 trial. With all the discussion around rituxan lately, this one is promising because it goes after the same target as rituxan, CD20, and therefore, B cells.



Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis

COPENHAGEN, Denmark, Dec. 13, 2007 – Genmab A/S (OMX: GEN) announced today details of a planned Phase II study of ofatumumab (HuMax-CD20) for the treatment of relapsing remitting multiple sclerosis (RRMS). Approximately 324 patients will be enrolled in the study which will be conducted under Genmab’s collaboration with GlaxoSmithKline (GSK). The study is expected to begin in the first quarter of 2008.

Ofatumumab is an investigational, fully human, next generation monoclonal antibody that targets a unique epitope of the CD20 receptor on the surface of B-cells. Other anti-CD20 antibodies currently available or in development bind to a different epitope on the CD20 receptor. Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline.

“Multiple sclerosis is a debilitating disease for which there are currently few treatments,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. “We hope our fully human antibody, ofatumumab, may offer another potential treatment option for patients suffering from this incapacitating disease.”

About the trial

The double blind randomized trial will consist of two parts. Part A will include approximately 36 patients in one of three increasing dose cohorts (100 mg, 300 mg or 700 mg of ofatumumab) randomized to receive ofatumumab or placebo. An independent data monitoring committee (IDMC) will evaluate the safety of each sequential cohort prior to progression to the next cohort. When all patients in Part A have had their week 4 MRI scan, the IDMC will evaluate the data before Part B of the study begins.

Part B will consist of a 48 week treatment period of approximately 288 patients. Patients will be randomized to treatment with 100 mg, 300 mg, or 700 mg of ofatumumab or placebo. After week 24, patients on an active dose will receive re-treatment with the same dose of ofatumumab or placebo. Patients on placebo will receive ofatumumab at the highest tolerated dose from Part A.

The objective of the study is to determine the safety and tolerability of three doses of ofatumumab and the dose response of ofatumumab on disease activity on MRI in patients with RRMS. The primary endpoints are safety and cumulative number of new Gd-enhanced lesions from week 8 to week 24.

http://www.pharmalive.com/News/index.cf ... egoryid=21
User avatar
dignan
Family Elder
 
Posts: 1608
Joined: Wed Aug 11, 2004 3:00 pm

Postby dignan » Tue Dec 18, 2007 9:47 am

The pipeline giveth and the pipeline taketh away. Bromely discovered a Merck Serono drug in phase 2 that wasn't on the list, Atacicept. Also, the company's drug Osteopontin is in phase 1 now. On the downside, the former Serono drugs in phase 1, MMP-12 inhibitor and JNK inhibitor are no longer listed on the Merck Serono pipeline. I will remove those 2 from the list. It's a good news / bad news day.
User avatar
dignan
Family Elder
 
Posts: 1608
Joined: Wed Aug 11, 2004 3:00 pm

Postby Frank » Wed Jan 16, 2008 1:22 am

MultiCell Technologies mentions an other agent in their pipeline named MCT-125 for treatment of fatigue in MS - yet there is not much info about it.
http://www.multicelltech.com/targets_pipeline.html

--Frank
Treatment: Gilenya since 01/2011, CCSVI both IJV ballooned 09/2010, Tysabri stopped after 24 Infusions and positive JCV antibody test, after LDN, ABX Wheldon Regime for 1 year.
Frank
Family Elder
 
Posts: 542
Joined: Wed Jan 03, 2007 4:00 pm
Location: Germany

Postby dignan » Thu Jan 17, 2008 11:10 pm

I removed Medarex’s MDX1100 from phase 1 because they are going forward with an ulcerative colitis trial, but the company’s website contains no mention of MDX1100 for MS that I could see.
User avatar
dignan
Family Elder
 
Posts: 1608
Joined: Wed Aug 11, 2004 3:00 pm

Postby dignan » Fri Jan 18, 2008 12:32 pm

I'm removing NNZ-2566 from the pipeline (phase 1) as Neuren makes no mention of MS on their site, and also say:

Neuren’s strategy is to undertake clinical trials for acute conditions, which are generally shorter and less expensive than those for chronic conditions. This strategy provides the most cost-effective means of increasing shareholder value while controlling risk.

Neuren decides which targets to pursue and which compounds to develop only after consideration of the cost and complexity of trials, the ease with which results can be validated, and assessment of market need and commercial opportunity.


Prove me wrong Bromley, prove me wrong...
User avatar
dignan
Family Elder
 
Posts: 1608
Joined: Wed Aug 11, 2004 3:00 pm

PreviousNext

Return to Drug Pipeline

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service